Jeffrey L Larson, Ph.D., DABT, is the president of Parady Consulting Inc.. Dr. Larson has broad experience in pharmaceutical drug development, providing expertise not only in preclinical toxicology, but in pharmacology proof-of-concept studies as well as pharmacokinetic modeling and clinical pharmacology trials. Dr. Larson has particular expertise in the area of biologics, including monoclonal antibodies.

Parady Consulting Inc. has authored regulatory submissions for biologics and drugs ranging from asthma to oncology, and from anti-viral and anti-fungal indications.

Our Capabilities Include:

• GLP Toxicology
• Pharmacokinetics
• Pharmacology
• Regulatory

Our broad base of experience from research into clinical trials, coupled with Project Management expertise, is likely to benefit your company and meet your project needs from early IND planning through the conduct of studies to support clinical trials, and continuing to market authorization.